Literature DB >> 26642331

Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse.

E Xue1,2, C Tresoldi3, E Sala1, A Crippa3, B Mazzi2, R Greco1, C Messina1, M G Carrabba1, M T Lupo Stanghellini1, S Marktel1, C Corti1, J Peccatori1, M Bernardi1, F Ciceri1, L Vago1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26642331     DOI： 10.1038/bmt.2015.296

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.

Authors:  Dario Campana; Wing Leung
Journal:  Br J Haematol       Date:  2013-05-09       Impact factor: 6.998

2.  The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

Authors:  Nona Shayegi; Michael Kramer; Martin Bornhäuser; Markus Schaich; Johannes Schetelig; Uwe Platzbecker; Christoph Röllig; Caroline Heiderich; Olfert Landt; Gerhard Ehninger; Christian Thiede
Journal:  Blood       Date:  2013-05-08       Impact factor: 22.113

3.  The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.

Authors:  Hiroyasu Ogawa; Hiroya Tamaki; Kazuhiro Ikegame; Toshihiro Soma; Manabu Kawakami; Akihiro Tsuboi; Eui Ho Kim; Naoki Hosen; Masaki Murakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Sumiyuki Nishida; Yusuke Oji; Yoshihiro Oka; Haruo Sugiyama
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

4.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Authors:  Jan Krönke; Richard F Schlenk; Kai-Ole Jensen; Florian Tschürtz; Andrea Corbacioglu; Verena I Gaidzik; Peter Paschka; Shiva Onken; Karina Eiwen; Marianne Habdank; Daniela Späth; Michael Lübbert; Mohammed Wattad; Thomas Kindler; Helmut R Salih; Gerhard Held; David Nachbaur; Marie von Lilienfeld-Toal; Ulrich Germing; Detlef Haase; Hans-Günther Mergenthaler; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Authors:  M Ryan Corces-Zimmerman; Wan-Jen Hong; Irving L Weissman; Bruno C Medeiros; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

6.  Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.

Authors:  Hans Beier Ommen; Susanne Schnittger; Jelena V Jovanovic; Ingrid Beier Ommen; Henrik Hasle; Mette Østergaard; David Grimwade; Peter Hokland
Journal:  Blood       Date:  2009-11-09       Impact factor: 22.113

7.  Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.

Authors:  Jan Krönke; Lars Bullinger; Veronica Teleanu; Florian Tschürtz; Verena I Gaidzik; Michael W M Kühn; Frank G Rücker; Karlheinz Holzmann; Peter Paschka; Silke Kapp-Schwörer; Daniela Späth; Thomas Kindler; Marcus Schittenhelm; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Richard F Schlenk; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

8.  Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

Authors:  Daniela Cilloni; Aline Renneville; Fabienne Hermitte; Robert K Hills; Sarah Daly; Jelena V Jovanovic; Enrico Gottardi; Milena Fava; Susanne Schnittger; Tamara Weiss; Barbara Izzo; Josep Nomdedeu; Adrian van der Heijden; Bert A van der Reijden; Joop H Jansen; Vincent H J van der Velden; Hans Ommen; Claude Preudhomme; Giuseppe Saglio; David Grimwade
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

9.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Authors:  Susanne Schnittger; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Frank Dicker; Brunangelo Falini; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

Review 10.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Authors:  David Grimwade; Sylvie D Freeman
Journal:  Blood       Date:  2014-07-21       Impact factor: 22.113
View more
  2 in total

1.  High expression of microRNA-500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.

Authors:  Gaoqi Zhang; Jinlong Shi; Xinrui Yang; Xinpei Zhang; Lingxiu Zhang; Jilei Zhang; Siyuan Yang; Jing Wang; Kai Hu; Xiaoyan Ke; Lin Fu
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

2.  Quantitative PCR-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study.

Authors:  Valentina Gambacorta; Riccardo Parolini; Elisabetta Xue; Raffaella Greco; Evelien E Bouwmans; Cristina Toffalori; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Alessandro Ambrosi; Benedetta Mazzi; Wietse Mulder; Consuelo Corti; Jacopo Peccatori; Fabio Ciceri; Luca Vago
Journal:  Haematologica       Date:  2020-09-10       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.